ArticleMultiple sclerosis and related disorders2021
COVID-19 severity and outcome in multiple sclerosis: Results of a national, registry-based, matched cohort study.
Article in Multiple sclerosis and related disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- COVID-19 severity among patients with multiple sclerosis treated with cladribine: A systematic review and meta-analysis.Multiple sclerosis and related disorders · 2022Pooled it
- Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies.Multiple sclerosis and related disorders · 2022Pooled it
- Long COVID in People With Multiple Sclerosis and Related Disorders: A Multicenter Cross-Sectional Study.Annals of clinical and translational neurology · 2025Article
- Quantitatively assessing the impact of the quality of SNOMED CT subtype hierarchy on cohort queries.Journal of the American Medical Informatics Association : JAMIA · 2025Article
- COVID-19 risk factors and outcomes in individuals with stiff person syndrome spectrum disorders before and after omicron.Orphanet journal of rare diseases · 2024Article
- An Interactive Information Visualization System for Temporal Queries in a Large-scale COVID-19 EHR Dataset (COVID-SPHERE): development and qualitative evaluation.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2024Article
- Optimizing Medication Querying Using Ontology-Driven Approach with OMOP: with an application to a large-scale COVID-19 EHR dataset.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2024Article
- COVID-19 and Health Outcomes in People with Multiple Sclerosis: A Population-Based Study in Italy.Life (Basel, Switzerland) · 2023Article
- Modifiable risk factors of COVID-19 in patients with multiple sclerosis: a single-centre case-control study.Journal of neurology · 2023Article
- Effectiveness of BBIBP-CorV vaccine in preventing SARS-CoV2 infection and severe outcomes in people living with multiple sclerosis: A population-based study.Multiple sclerosis and related disorders · 2023Observational
- Electronic health record data for assessing risk of hospitalization for COVID-19: Methodological considerations applied to multiple sclerosis.Multiple sclerosis and related disorders · 2023Article
- Vaccination and immunotherapies in neuroimmunological diseases.Nature reviews. Neurology · 2022Review
- Temporal Cohort Logic.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2022Article
- Keep your eyes on the prize: Tackling breakthrough COVID-19 in MS patients.Multiple sclerosis (Houndmills, Basingstoke, England) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRisk factors associated with coronavirus disease 2019 (COVID-19) severity in patients with multiple sclerosis (MS) have been described. Recent improvements in supportive care measures and increased testing capacity may modify the risk of severe COVID-19 outcome in MS patients. This retrospective study evaluates the severity and outcome of COVID-19 in MS and characterizes temporal trends over the course of the pandemic in the United States.
methodsWe conducted a comparative cohort study using de-identified electronic health record (EHR) claims-based data. MS patients diagnosed with COVID-19 between February 2, 2020 and October 13, 2020 were matched (1:2) to a control group using propensity score analysis. The primary outcome was a composite of intensive care unit (ICU) admission, mechanical ventilation, and/or death.
resultsA total of 2,529 patients (843 MS and 1,686 matched controls) were included. Non-ambulatory and pre-existing comorbidities were independent risk factors for COVID-19 severity. The risk for the severe composite outcome was lower in the late cohorts compared with the early cohorts.
conclusionsThe majority of MS patients actively treated with a disease-modifying therapy (DMT) had mild disease. The observed trend toward a reduction in severity risk in recent months suggests an improvement in COVID-19 outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.